Peer-influenced content. Sources you trust. No registration required. This is HCN.
Dana-Farber Cancer Institute
Explore the groundbreaking findings from the TROPiCS-02 study, revealing sacituzumab govitecan as a potential game-changer in the treatment of endocrine refractory metastatic hormone receptor-positive breast cancer.
Oncology, Medical July 3rd 2023
Academy of Managed Care Pharmacy (AMCP)
On July 11, 2023, participate in the AMCP PIE Webinar to learn more about the potential of VP-102, an investigational medication for molluscum contagiosum that is now undergoing FDA assessment.
Clinical Pharmacology June 30th 2023
Journal of the American Pharmacists Association (JAPhA)
Unpacking the landmark summit led by the American Pharmacists Association, it becomes clear that there is a pressing need and opportunity to expand healthcare coverage for pharmacists’ patient care services, promising substantial impacts on patient care and health systems.
Journal of Clinical Pathways
Understand the profound implications of Dr. Vidal’s latest research on racial disparities in NGS testing for advanced non-small cell lung cancer, revealing a systemic issue that spans across practices and extends to the level of individual physicians.
Oncology, Medical June 20th 2023
Cancer Therapy Advisor
Explore the latest findings from the VESPER trial that suggest a promising shift in bladder cancer treatment strategy, potentially setting a new standard for neoadjuvant therapy.
Neurology Advisor
Age, a Critical Moderator in Anxiety/Depression and Cognitive Outcomes in MS In recent findings from the ACTRIMS Forum 2023, researchers underscored the crucial role of age in the relationship between mental health and cognitive outcomes in patients with multiple sclerosis (MS). Key Points: “Considering age is necessary when exploring the links between depression or anxiety and cognition in people with MS.” Researchers from the University of Toronto
Geriatrics June 13th 2023